Abivax shares sink after key trial results for inflammatory bowel drug

Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment ​showed strong efficacy.